ReNewVax develops pneumococcal vaccines to prevent life-threatening bacterial infections.
ReNewVax has raised $326K in total funding. The most recent round was Pre-Seed. The last funding was announced in October 2024.
ReNewVax's investors include SFC Capital.
ReNewVax is headquartered in Liverpool, United Kingdom.
ReNewVax develops pneumococcal vaccines to prevent life-threatening bacterial infections.
ReNewVax is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ReNewVax — Funding & Investors." VCBacked, October 18, 2024, https://www.vcbacked.co/company/renewvax. Accessed August 13, 2026.
VCBacked. (2024). ReNewVax — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/renewvax
{{cite web |title=ReNewVax — Funding & Investors |url=https://www.vcbacked.co/company/renewvax |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated